Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
17 mars 2021 07h00 HE
|
Imara, Inc.
Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower...
Imara Reports Full Year 2020 Financial Results and Business Highlights
05 mars 2021 07h00 HE
|
Imara, Inc.
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a open label extension clinical...
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
26 févr. 2021 21h30 HE
|
Imara, Inc.
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
19 févr. 2021 07h00 HE
|
Imara, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
20 janv. 2021 07h00 HE
|
Imara, Inc.
BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
06 janv. 2021 07h00 HE
|
Imara, Inc.
Promising reductions in rate of VOCs/SCPCs observed in monotherapy IMR-687 treated patients vs. placebo Biomarker data from both monotherapy IMR-687 and combination IMR-687+HU groups show improvement...
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
07 déc. 2020 07h00 HE
|
Imara, Inc.
Preliminary data as of August 2020 from ongoing Phase 2a open label extension trial showed increases in HbF percentage and F-cells after approximately six months of treatment Case reports showed...
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
30 nov. 2020 07h00 HE
|
Imara, Inc.
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
17 nov. 2020 07h00 HE
|
Imara, Inc.
BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
05 nov. 2020 07h00 HE
|
Imara, Inc.
Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease ...